Symposium 2: What have CVOT taught us about microvascular impact in T2DM?
DOI:
https://doi.org/10.47196/diab.v56i3Sup.491Keywords:
diabetes mellitus, drugsAbstract
In the last years of the 20th century, efforts were concentrated on demonstrating whether bringing blood glucose levels as close as possible to normal was associated with a reduction in complications of diabetes (DM), trying to avoid endothelial damage of glucotoxicity. First results showed benefits at microvascular level, but not in macrovascular complications. In 2008, FDA demanded that randomised placebo-controlled CVOTs had to be done to demonstrate cardiovascular (CV) safety before approval of new drugs for DM. Clinical trials with DPP4 inhibitors showed CV safety and some kidney benefits.
But everything changes after the publication of the EMPA REG OUTCOME, where empagliflozin demonstrated a significant reduction in the primary trial objective, without changes in the risk of acute heart attack or stroke, recognized by this time as the main cause of death in T2DM, and a significant reduction in the risk of hospitalization for heart failure and surprising renal benefits.
References
I. Williams D, Nawaz A, Evans M. Renal outcomes in type 2 diabetes. A review of cardiovascular and renal outcome trials. Diabetes Ther 2020;11:369-386.
II. Lin D, Lee J, Hung Ch, Chen W. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-nalysis of randomised clinical trials. Diabetologia 2021;64:2676-2686.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
